Moderna (NASDAQ:MRNA) Trading 3.6% Higher – Here’s Why

Moderna, Inc. (NASDAQ:MRNA) shares rose 3.6% during mid-day trading on Tuesday . The company traded as high as $143.74 and last traded at $145.3960. 2,427,647 shares changed hands during trading, a decline of 79% from the average daily volume of 11,434,615 shares. The stock had previously closed at $140.34.

Key Headlines Impacting Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna’s personalized melanoma vaccine with Merck delivered positive late-stage trial results, reinforcing the potential for a commercially significant oncology business beyond COVID-19 vaccines. The development has been a major driver of the stock’s recent rally. Moderna Stock Climbs Following Melanoma Trial Success and Vaccine Approval
• Positive Sentiment: The FDA approved Moderna’s new mRNA seasonal flu vaccine for adults, expanding the company’s commercial vaccine opportunity and validating its mRNA platform. FDA Approves New mRNA Flu Vaccine for Adults
• Positive Sentiment: Brookline Capital Markets raised its 2026–2028 EPS forecasts and maintained a “Buy” rating, including a projected return to profitability in 2028. The revisions suggest improving expectations for Moderna’s cost structure and pipeline revenue. Brookline Capital Markets Estimates
• Positive Sentiment: Commentator Jim Cramer argued that Moderna’s heavy short interest could fuel additional gains if bearish investors continue covering positions. Elevated call-option activity and short-squeeze screens are adding speculative buying interest. Jim Cramer Discusses Moderna’s Short-Squeeze Potential
• Neutral Sentiment: Moderna will present at healthcare investor conferences in September, creating potential catalysts for updates on its pipeline, commercial plans and financial outlook.
• Negative Sentiment: GSK advanced a competing mRNA flu vaccine into Phase III development. While Moderna currently has a first-mover advantage, the move could increase long-term competition in a market investors are increasingly valuing. GSK Advances Rival mRNA Flu Vaccine
• Negative Sentiment: After more than doubling in August, MRNA may be experiencing profit-taking and heightened volatility. Brookline also modestly reduced its longer-term 2029–2030 EPS estimates, tempering some of the bullish outlook.

Analysts Set New Price Targets

A number of research analysts have recently commented on the stock. William Blair began coverage on shares of Moderna in a report on Friday, August 28th. They issued an “outperform” rating on the stock. Deutsche Bank Aktiengesellschaft began coverage on shares of Moderna in a report on Friday, August 28th. They set a “hold” rating for the company. Brookline Capital Markets reissued a “buy” rating on shares of Moderna in a research report on Wednesday, August 19th. Weiss Ratings restated a “sell (d-)” rating on shares of Moderna in a research note on Friday, June 12th. Finally, The Goldman Sachs Group raised their target price on shares of Moderna from $67.00 to $120.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 19th. Seven equities research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and four have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $80.53.

Moderna Stock Performance

The business’s 50-day moving average price is $82.40 and its 200-day moving average price is $62.12. The company has a current ratio of 2.29, a quick ratio of 2.18 and a debt-to-equity ratio of 0.09. The stock has a market cap of $60.21 billion, a PE ratio of -18.87 and a beta of 1.10.

Moderna (NASDAQ:MRNA) last announced its earnings results on Friday, July 31st. The company reported ($1.97) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.03) by $0.06. The company had revenue of $145.00 million for the quarter, compared to analyst estimates of $102.93 million. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%.The firm’s quarterly revenue was up 2.1% compared to the same quarter last year. During the same period in the prior year, the company posted ($2.13) EPS. As a group, equities research analysts expect that Moderna, Inc. will post -6.09 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, President Stephen Hoge sold 53,336 shares of Moderna stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $51.37, for a total transaction of $2,739,870.32. Following the completion of the transaction, the president directly owned 1,483,848 shares of the company’s stock, valued at $76,225,271.76. The trade was a 3.47% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 10.80% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in MRNA. BlackRock Inc. acquired a new position in Moderna during the second quarter worth about $2,142,877,000. California State Teachers Retirement System raised its holdings in Moderna by 6,698.1% in the 2nd quarter. California State Teachers Retirement System now owns 27,681,318 shares of the company’s stock valued at $1,938,523,000 after acquiring an additional 27,274,128 shares during the last quarter. Capital World Investors purchased a new position in Moderna in the 4th quarter worth approximately $378,299,000. Theleme Partners LLP purchased a new position in Moderna in the 2nd quarter worth approximately $564,272,000. Finally, Alyeska Investment Group L.P. purchased a new position in Moderna in the 4th quarter worth approximately $95,209,000. Hedge funds and other institutional investors own 75.33% of the company’s stock.

About Moderna

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.